Abstract 462P
Background
The aim of this study was to identify correlates of cognitive function among cancer survivors attending rehabilitation in a community setting.
Methods
Participants were 35 cancer patients who had reported memory issues and were screened by an occupational therapist for cognitive dysfunction. Using baseline data, descriptive and bivariate analyses were performed to detail the cognitive function of study sample and to identify its correlates.
Results
Study sample was predominantly female (94.7%) with breast cancer (65.8%) who had received chemotherapy (77.1%) and hormonal therapy (51.5%). Mean age was 53.8 ± 10.3 years and mean years since diagnosis was 4.9 ± 3.3 years. Mean scores of cognitive performances were within the norms for attention (digit span forward test; 7.5 ± 1.4), working memory (digit span backward test; 5.4 ± 1.3), processing speed (trail making test A; 25.1 ± 5.5), and executive function (trail making test B; 68.3 ± 33.6). Mean scores of perceived cognitive ability (15.5 ± 4.1) and cognitive-related quality of life (9.8 ± 3.7), measured by the FACT-Cog, were below the norms. Cancer survivors with more years since diagnosis performed better in executive function (r = .45). Poorer working memory (r = -.38) and lower cognitive-related quality of life (r = -.41) were also found to associate with increased fatigue intensity. Although sleep duration and distress rating were not related to cognitive function, shorter sleep duration (r = -.35) and higher distress rating (r = .37) correlated with higher fatigue intensity. All results were statistically significant at p < 0.05.
Conclusions
Cancer survivors may report reduced perceived cognitive ability and cognitive-related quality of life despite adequate performance on objective tests. This discrepancy could be due to the relationship of fatigue to working memory. Global evaluation of cognitive function considers cognitive performance during periods of more intense fatigue while objective tests provide information on cognitive performance when tested at a particular time and fatigue level. Managing fatigue including addressing distress and sleep issues may be potential strategies that can be employed to support cognitive function.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract